Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease
Shots:
- Nurix to receive $45M upfront- up to $2.3B as milestones and royalties on sales- and will identify novel targets- utilizing its discovery platform & E3 ligases inducing degradation of targets. Nurix retains an option to co-develop and co-detail up to 2 programs with equal profit & loss sharing with split cost in the US- receives royalties on sales (Ex-US) & reduced milestones for opted programs
- Gilead to get an option to license drug candidates up to 5 targets developed by Nurix and get rights to develop & commercialize targeted protein degradation drugs for patients with cancer and other challenging diseases
- Nurix’s technology platform focuses on the manipulation of the ubiquitin system and its component E3 ligases- responsible for controlling protein levels in human cells
Ref: Gilead | Image: Gilead
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com